EUR 5.2 million for Belgian drug research

The Belgian drug discovery company Galapagos has been awarded a total of €5.2 million in grants from the Netherlands and the European Union for several drug development projects. The aim is to create candidate drugs for conditions such as bone and joint disease, as well as novel cancer drugs.

The largest share of the research funding - €2.9 million - has been put into the pot by the Dutch Ministries of Economic Affairs and Education, Culture and Science. Under the subsidy programme SmartMix, which encourages cooperation between companies, civil-society organisations and universities, the money will finance an eight-year programme aspiring to develop new disease models in order to speed up the discovery of new drugs for bone and joint diseases. A further €1.5 million comes from Top Institute Pharma.

In a four-year programme, Galapagos, the University Medical Centre Utrecht, the Hubrecht Institute of the Royal Netherlands Academy of Sciences and the Dutch biotechnology company Agamyxis will join forces in the search for novel cancer drugs.

Finally, two three-year projects studying cancer progression are receiving €0.8 million funding from the EU's research framework programmes. The studies will focus on time and cost effective development of anti-cancer compounds.

Welcoming the continued government support, Galapagos CEO Onno van de Stolpe said: "these grants enable us to accelerate our internal discovery activities in bone and joint diseases and also to apply our technologies in other areas of unmet medical need."

For further information, please visit:
http://www.glpg.com

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...